항체 탐색 시장 - 세계 업계 분석, 규모, 점유율, 성장, 동향, 예측(2032년)

The Antibody Discovery Market is set to achieve significant growth, driven by innovations and technological advancements that are reshaping the pharmaceutical and biotechnology sectors. By leveraging cutting-edge techniques such as phage display and hybridoma technology, the industry aims to deliver targeted and effective therapeutic solutions. These developments are critical for addressing complex diseases such as cancer, autoimmune disorders, and infectious diseases.

Market Insights

The global Antibody Discovery Market is projected to grow steadily, achieving a valuation of $8.88 billion by 2025 and $15.82 billion by 2032, with a CAGR of 8.60% during the forecast period. The market's expansion underscores its vital role in revolutionizing treatment modalities by providing highly specific and effective therapeutic interventions. Advances in artificial intelligence and personalized medicine further fuel the market's potential for innovation and revenue generation.

Key Market Drivers

• 1. Advancements in Biotechnology: The integration of high-throughput technologies, such as next-generation sequencing and advanced screening methods, is expediting antibody discovery. These innovations enhance efficiency, enabling faster identification of potential therapeutic antibodies.
• 2. Rising Demand for Personalized Medicine: Tailored therapies are gaining traction, driving the need for customized antibody-based treatments. This trend aligns with the shift toward precision medicine, focusing on individual patient profiles and targeted disease pathways.
• 3. Increased Prevalence of Chronic Diseases: The growing burden of cancer, autoimmune disorders, and other chronic illnesses emphasizes the demand for innovative therapeutic solutions, positioning the antibody discovery sector at the forefront of medical advancements.

Business Opportunities

• 1. Innovative Collaboration Models: Strategic partnerships with academic institutions, biotechnology firms, and contract research organizations present lucrative opportunities. These collaborations enable resource-sharing and expedite the discovery and development of novel therapeutic antibodies.
• 2. Integration of Artificial Intelligence: Leveraging AI algorithms enhances antibody design, screening, and optimization processes, accelerating the identification of high-affinity and highly specific antibodies. This technological integration offers a competitive edge to market players.
• 3. Emerging Markets in South Asia & Pacific: Countries in this region, including India, China, and Australia, are investing heavily in biomedical research. Collaborative initiatives between academic institutions and pharmaceutical companies amplify the region's potential as a hub for antibody discovery.

Regional Analysis

• Europe: The region is emerging as a dominant force in the market, driven by a robust research infrastructure and a proactive regulatory environment. Europe's streamlined approval processes and focus on innovation foster market growth and attract significant investments.
• North America: As a global leader in biotechnology and pharmaceutical research, North America's advanced infrastructure and strong funding ecosystem position it as a key contributor to market expansion.
• South Asia & Pacific: This region is witnessing the fastest growth, fueled by increased research initiatives and collaborations aimed at addressing complex diseases. The region's commitment to advancing life sciences strengthens its role in the global market.

Market Challenges

• 1. Regulatory Stringency: Stringent regulatory frameworks governing the development and approval of antibody-based therapeutics can slow market progression. Companies must ensure compliance to gain market dominance.
• 2. Technological Complexity: The integration of diverse platforms and techniques, such as phage display and hybridoma, requires substantial expertise and investment. Addressing these challenges is essential for streamlined operations.

Recent Developments

• 1. Strategic Collaborations: Regeneron Pharmaceuticals, Inc., and Intellia Therapeutics, Inc., expanded their research collaboration in 2023 to develop in vivo CRISPR-based gene-editing therapies targeting neurological and muscular diseases.
• 2. Strengthening R&D: In September 2022, Abzena announced strategic initiatives to enhance its research capabilities in Cambridge, reinforcing its position in biologics and antibody drug conjugates.

Key Players

Prominent organizations driving innovation in the Antibody Discovery Market include:

• Alcami Corporation, Inc.
• BASF SE
• Bioduro-Sundia
• Bruker
• Cambrex Corporation
• Croda International Plc
• Aragen Life Sciences Pvt. Ltd
• Eurofins DiscoverX Corporation
• NanoCellect Biomedical
• Sartorius AG

Market Segmentation

1. By Method:

Phage Display Hybridoma Others

2. By Antibody Type:

Humanized Antibody Human Antibody Chimeric Antibody Murine Antibody

3. By End-Use:

Pharmaceutical and Biotechnology Industry Research Laboratory Academic Laboratory

4. By Region:

North America Europe East Asia South Asia & Oceania Latin America Middle East & Africa

Table of Contents

1. Executive Summary

• 1.1. Global Antibody Discovery Market Snapshot
• 1.2. Future Projections
• 1.3. Key Market Trends
• 1.4. Regional Snapshot, by Value, 2025
• 1.5. Analyst Recommendations

2. Market Overview

• 2.1. Market Definitions and Segmentations
• 2.2. Market Dynamics
  • 2.2.1. Drivers
  • 2.2.2. Restraints
  • 2.2.3. Market Opportunities
• 2.3. Value Chain Analysis
• 2.4. Porter's Five Forces Analysis
• 2.5. COVID-19 Impact Analysis
  • 2.5.1. Supply
  • 2.5.2. Demand
• 2.6. Impact of Ukraine-Russia Conflict
• 2.7. Economic Overview
  • 2.7.1. World Economic Projections
• 2.8. PESTLE Analysis

3. Global Antibody Discovery Market Outlook, 2019 - 2032

• 3.1. Global Antibody Discovery Market Outlook, by Method, Value (US$ Bn), 2019 - 2032
  • 3.1.1. Key Highlights
    • 3.1.1.1. Phage Display
    • 3.1.1.2. Hybridoma
    • 3.1.1.3. Others
• 3.2. Global Antibody Discovery Market Outlook, by Antibody Type, Value (US$ Bn), 2019 - 2032
  • 3.2.1. Key Highlights
    • 3.2.1.1. Humanized Antibody
    • 3.2.1.2. Human Antibody
    • 3.2.1.3. Chimeric Antibody
    • 3.2.1.4. Murine Antibody
• 3.3. Global Antibody Discovery Market Outlook, by End-use, Value (US$ Bn), 2019 - 2032
  • 3.3.1. Key Highlights
    • 3.3.1.1. Pharmaceutical and Biotechnology industry
    • 3.3.1.2. Research laboratory
    • 3.3.1.3. Academic laboratory
• 3.4. Global Antibody Discovery Market Outlook, by Region, Value (US$ Bn), 2019 - 2032
  • 3.4.1. Key Highlights
    • 3.4.1.1. North America
    • 3.4.1.2. Europe
    • 3.4.1.3. Asia Pacific
    • 3.4.1.4. Latin America
    • 3.4.1.5. Middle East & Africa

4. North America Antibody Discovery Market Outlook, 2019 - 2032

• 4.1. North America Antibody Discovery Market Outlook, by Method, Value (US$ Bn), 2019 - 2032
  • 4.1.1. Key Highlights
    • 4.1.1.1. Phage Display
    • 4.1.1.2. Hybridoma
    • 4.1.1.3. Others
• 4.2. North America Antibody Discovery Market Outlook, by Antibody Type, Value (US$ Bn), 2019 - 2032
  • 4.2.1. Key Highlights
    • 4.2.1.1. Humanized Antibody
    • 4.2.1.2. Human Antibody
    • 4.2.1.3. Chimeric Antibody
    • 4.2.1.4. Murine Antibody
• 4.3. North America Antibody Discovery Market Outlook, by End-use, Value (US$ Bn), 2019 - 2032
  • 4.3.1. Key Highlights
    • 4.3.1.1. Pharmaceutical and Biotechnology industry
    • 4.3.1.2. Research laboratory
    • 4.3.1.3. Academic laboratory
  • 4.3.2. BPS Analysis/Market Attractiveness Analysis
• 4.4. North America Antibody Discovery Market Outlook, by Country, Value (US$ Bn), 2019 - 2032
  • 4.4.1. Key Highlights
    • 4.4.1.1. Antibody Discovery Market by Method, Value (US$ Bn), 2019 - 2032
    • 4.4.1.2. Antibody Discovery Market by Antibody Type, Value (US$ Bn), 2019 - 2032
    • 4.4.1.3. Antibody Discovery Market by End-use, Value (US$ Bn), 2019 - 2032
    • 4.4.1.4. Canada Antibody Discovery Market by Method, Value (US$ Bn), 2019 - 2032
    • 4.4.1.5. Canada Antibody Discovery Market by Antibody Type, Value (US$ Bn), 2019 - 2032
    • 4.4.1.6. Canada Antibody Discovery Market by End-use, Value (US$ Bn), 2019 - 2032
  • 4.4.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Antibody Discovery Market Outlook, 2019 - 2032

• 5.1. Europe Antibody Discovery Market Outlook, by Method, Value (US$ Bn), 2019 - 2032
  • 5.1.1. Key Highlights
    • 5.1.1.1. Phage Display
    • 5.1.1.2. Hybridoma
    • 5.1.1.3. Others
• 5.2. Europe Antibody Discovery Market Outlook, by Antibody Type, Value (US$ Bn), 2019 - 2032
  • 5.2.1. Key Highlights
    • 5.2.1.1. Humanized Antibody
    • 5.2.1.2. Human Antibody
    • 5.2.1.3. Chimeric Antibody
    • 5.2.1.4. Murine Antibody
• 5.3. Europe Antibody Discovery Market Outlook, by End-use, Value (US$ Bn), 2019 - 2032
  • 5.3.1. Key Highlights
    • 5.3.1.1. Pharmaceutical and Biotechnology industry
    • 5.3.1.2. Research laboratory
    • 5.3.1.3. Academic laboratory
  • 5.3.2. BPS Analysis/Market Attractiveness Analysis
• 5.4. Europe Antibody Discovery Market Outlook, by Country, Value (US$ Bn), 2019 - 2032
  • 5.4.1. Key Highlights
    • 5.4.1.1. Germany Antibody Discovery Market by Method, Value (US$ Bn), 2019 - 2032
    • 5.4.1.2. Germany Antibody Discovery Market by Antibody Type, Value (US$ Bn), 2019 - 2032
    • 5.4.1.3. Germany Antibody Discovery Market by End-use, Value (US$ Bn), 2019 - 2032
    • 5.4.1.4. U.K. Antibody Discovery Market by Method, Value (US$ Bn), 2019 - 2032
    • 5.4.1.5. U.K. Antibody Discovery Market by Antibody Type, Value (US$ Bn), 2019 - 2032
    • 5.4.1.6. U.K. Antibody Discovery Market by End-use, Value (US$ Bn), 2019 - 2032
    • 5.4.1.7. France Antibody Discovery Market by Method, Value (US$ Bn), 2019 - 2032
    • 5.4.1.8. France Antibody Discovery Market by Antibody Type, Value (US$ Bn), 2019 - 2032
    • 5.4.1.9. France Antibody Discovery Market by End-use, Value (US$ Bn), 2019 - 2032
    • 5.4.1.10. Italy Antibody Discovery Market by Method, Value (US$ Bn), 2019 - 2032
    • 5.4.1.11. Italy Antibody Discovery Market by Antibody Type, Value (US$ Bn), 2019 - 2032
    • 5.4.1.12. Italy Antibody Discovery Market by End-use, Value (US$ Bn), 2019 - 2032
    • 5.4.1.13. Turkey Antibody Discovery Market by Method, Value (US$ Bn), 2019 - 2032
    • 5.4.1.14. Turkey Antibody Discovery Market by Antibody Type, Value (US$ Bn), 2019 - 2032
    • 5.4.1.15. Turkey Antibody Discovery Market by End-use, Value (US$ Bn), 2019 - 2032
    • 5.4.1.16. Russia Antibody Discovery Market by Method, Value (US$ Bn), 2019 - 2032
    • 5.4.1.17. Russia Antibody Discovery Market by Antibody Type, Value (US$ Bn), 2019 - 2032
    • 5.4.1.18. Russia Antibody Discovery Market by End-use, Value (US$ Bn), 2019 - 2032
    • 5.4.1.19. Rest of Europe Antibody Discovery Market by Method, Value (US$ Bn), 2019 - 2032
    • 5.4.1.20. Rest of Europe Antibody Discovery Market by Antibody Type, Value (US$ Bn), 2019 - 2032
    • 5.4.1.21. Rest of Europe Antibody Discovery Market by End-use, Value (US$ Bn), 2019 - 2032
  • 5.4.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Antibody Discovery Market Outlook, 2019 - 2032

• 6.1. Asia Pacific Antibody Discovery Market Outlook, by Method, Value (US$ Bn), 2019 - 2032
  • 6.1.1. Key Highlights
    • 6.1.1.1. Phage Display
    • 6.1.1.2. Hybridoma
    • 6.1.1.3. Others
• 6.2. Asia Pacific Antibody Discovery Market Outlook, by Antibody Type, Value (US$ Bn), 2019 - 2032
  • 6.2.1. Key Highlights
    • 6.2.1.1. Humanized Antibody
    • 6.2.1.2. Human Antibody
    • 6.2.1.3. Chimeric Antibody
    • 6.2.1.4. Murine Antibody
• 6.3. Asia Pacific Antibody Discovery Market Outlook, by End-use, Value (US$ Bn), 2019 - 2032
  • 6.3.1. Key Highlights
    • 6.3.1.1. Pharmaceutical and Biotechnology industry
    • 6.3.1.2. Research laboratory
    • 6.3.1.3. Academic laboratory
  • 6.3.2. BPS Analysis/Market Attractiveness Analysis
• 6.4. Asia Pacific Antibody Discovery Market Outlook, by Country, Value (US$ Bn), 2019 - 2032
  • 6.4.1. Key Highlights
    • 6.4.1.1. China Antibody Discovery Market by Method, Value (US$ Bn), 2019 - 2032
    • 6.4.1.2. China Antibody Discovery Market by Antibody Type, Value (US$ Bn), 2019 - 2032
    • 6.4.1.3. China Antibody Discovery Market by End-use, Value (US$ Bn), 2019 - 2032
    • 6.4.1.4. Japan Antibody Discovery Market by Method, Value (US$ Bn), 2019 - 2032
    • 6.4.1.5. Japan Antibody Discovery Market by Antibody Type, Value (US$ Bn), 2019 - 2032
    • 6.4.1.6. Japan Antibody Discovery Market by End-use, Value (US$ Bn), 2019 - 2032
    • 6.4.1.7. South Korea Antibody Discovery Market by Method, Value (US$ Bn), 2019 - 2032
    • 6.4.1.8. South Korea Antibody Discovery Market by Antibody Type, Value (US$ Bn), 2019 - 2032
    • 6.4.1.9. South Korea Antibody Discovery Market by End-use, Value (US$ Bn), 2019 - 2032
    • 6.4.1.10. India Antibody Discovery Market by Method, Value (US$ Bn), 2019 - 2032
    • 6.4.1.11. India Antibody Discovery Market by Antibody Type, Value (US$ Bn), 2019 - 2032
    • 6.4.1.12. India Antibody Discovery Market by End-use, Value (US$ Bn), 2019 - 2032
    • 6.4.1.13. Southeast Asia Antibody Discovery Market by Method, Value (US$ Bn), 2019 - 2032
    • 6.4.1.14. Southeast Asia Antibody Discovery Market by Antibody Type, Value (US$ Bn), 2019 - 2032
    • 6.4.1.15. Southeast Asia Antibody Discovery Market by End-use, Value (US$ Bn), 2019 - 2032
    • 6.4.1.16. Rest of Asia Pacific Antibody Discovery Market by Method, Value (US$ Bn), 2019 - 2032
    • 6.4.1.17. Rest of Asia Pacific Antibody Discovery Market by Antibody Type, Value (US$ Bn), 2019 - 2032
    • 6.4.1.18. Rest of Asia Pacific Antibody Discovery Market by End-use, Value (US$ Bn), 2019 - 2032
  • 6.4.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Antibody Discovery Market Outlook, 2019 - 2032

• 7.1. Latin America Antibody Discovery Market Outlook, by Method, Value (US$ Bn), 2019 - 2032
  • 7.1.1. Key Highlights
    • 7.1.1.1. Phage Display
    • 7.1.1.2. Hybridoma
    • 7.1.1.3. Others
• 7.2. Latin America Antibody Discovery Market Outlook, by Antibody Type, Value (US$ Bn), 2019 - 2032
  • 7.2.1. Key Highlights
    • 7.2.1.1. Humanized Antibody
    • 7.2.1.2. Human Antibody
    • 7.2.1.3. Chimeric Antibody
    • 7.2.1.4. Murine Antibody
• 7.3. Latin America Antibody Discovery Market Outlook, by End-use, Value (US$ Bn), 2019 - 2032
  • 7.3.1. Key Highlights
    • 7.3.1.1. Pharmaceutical and Biotechnology industry
    • 7.3.1.2. Research laboratory
    • 7.3.1.3. Academic laboratory
  • 7.3.2. BPS Analysis/Market Attractiveness Analysis
• 7.4. Latin America Antibody Discovery Market Outlook, by Country, Value (US$ Bn), 2019 - 2032
  • 7.4.1. Key Highlights
    • 7.4.1.1. Brazil Antibody Discovery Market by Method, Value (US$ Bn), 2019 - 2032
    • 7.4.1.2. Brazil Antibody Discovery Market by Antibody Type, Value (US$ Bn), 2019 - 2032
    • 7.4.1.3. Brazil Antibody Discovery Market by End-use, Value (US$ Bn), 2019 - 2032
    • 7.4.1.4. Mexico Antibody Discovery Market by Method, Value (US$ Bn), 2019 - 2032
    • 7.4.1.5. Mexico Antibody Discovery Market by Antibody Type, Value (US$ Bn), 2019 - 2032
    • 7.4.1.6. Mexico Antibody Discovery Market by End-use, Value (US$ Bn), 2019 - 2032
    • 7.4.1.7. Argentina Antibody Discovery Market by Method, Value (US$ Bn), 2019 - 2032
    • 7.4.1.8. Argentina Antibody Discovery Market by Antibody Type, Value (US$ Bn), 2019 - 2032
    • 7.4.1.9. Argentina Antibody Discovery Market by End-use, Value (US$ Bn), 2019 - 2032
    • 7.4.1.10. Rest of Latin America Antibody Discovery Market by Method, Value (US$ Bn), 2019 - 2032
    • 7.4.1.11. Rest of Latin America Antibody Discovery Market by Antibody Type, Value (US$ Bn), 2019 - 2032
    • 7.4.1.12. Rest of Latin America Antibody Discovery Market by End-use, Value (US$ Bn), 2019 - 2032
  • 7.4.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Antibody Discovery Market Outlook, 2019 - 2032

• 8.1. Middle East & Africa Antibody Discovery Market Outlook, by Method, Value (US$ Bn), 2019 - 2032
  • 8.1.1. Key Highlights
    • 8.1.1.1. Phage Display
    • 8.1.1.2. Hybridoma
    • 8.1.1.3. Others
• 8.2. Middle East & Africa Antibody Discovery Market Outlook, by Antibody Type, Value (US$ Bn), 2019 - 2032
  • 8.2.1. Key Highlights
    • 8.2.1.1. Humanized Antibody
    • 8.2.1.2. Human Antibody
    • 8.2.1.3. Chimeric Antibody
    • 8.2.1.4. Murine Antibody
• 8.3. Middle East & Africa Antibody Discovery Market Outlook, by End-use, Value (US$ Bn), 2019 - 2032
  • 8.3.1. Key Highlights
    • 8.3.1.1. Pharmaceutical and Biotechnology industry
    • 8.3.1.2. Research laboratory
    • 8.3.1.3. Academic laboratory
  • 8.3.2. BPS Analysis/Market Attractiveness Analysis
• 8.4. Middle East & Africa Antibody Discovery Market Outlook, by Country, Value (US$ Bn), 2019 - 2032
  • 8.4.1. Key Highlights
    • 8.4.1.1. GCC Antibody Discovery Market by Method, Value (US$ Bn), 2019 - 2032
    • 8.4.1.2. GCC Antibody Discovery Market by Antibody Type, Value (US$ Bn), 2019 - 2032
    • 8.4.1.3. GCC Antibody Discovery Market by End-use, Value (US$ Bn), 2019 - 2032
    • 8.4.1.4. South Africa Antibody Discovery Market by Method, Value (US$ Bn), 2019 - 2032
    • 8.4.1.5. South Africa Antibody Discovery Market by Antibody Type, Value (US$ Bn), 2019 - 2032
    • 8.4.1.6. South Africa Antibody Discovery Market by End-use, Value (US$ Bn), 2019 - 2032
    • 8.4.1.7. Egypt Antibody Discovery Market by Method, Value (US$ Bn), 2019 - 2032
    • 8.4.1.8. Egypt Antibody Discovery Market by Antibody Type, Value (US$ Bn), 2019 - 2032
    • 8.4.1.9. Egypt Antibody Discovery Market by End-use, Value (US$ Bn), 2019 - 2032
    • 8.4.1.10. Nigeria Antibody Discovery Market by Method, Value (US$ Bn), 2019 - 2032
    • 8.4.1.11. Nigeria Antibody Discovery Market by Antibody Type, Value (US$ Bn), 2019 - 2032
    • 8.4.1.12. Nigeria Antibody Discovery Market by End-use, Value (US$ Bn), 2019 - 2032
    • 8.4.1.13. Rest of Middle East & Africa Antibody Discovery Market by Method, Value (US$ Bn), 2019 - 2032
    • 8.4.1.14. Rest of Middle East & Africa Antibody Discovery Market by Antibody Type, Value (US$ Bn), 2019 - 2032
    • 8.4.1.15. Rest of Middle East & Africa Antibody Discovery Market by End-use, Value (US$ Bn), 2019 - 2032
  • 8.4.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

• 9.1. By Method vs by Antibody Type Heat map
• 9.2. Company Market Share Analysis, 2025
• 9.3. Competitive Dashboard
• 9.4. Company Profiles
  • 9.4.1. Alcami Corporation, Inc.
    • 9.4.1.1. Company Overview
    • 9.4.1.2. Product Portfolio
    • 9.4.1.3. Financial Overview
    • 9.4.1.4. Business Strategies and Development
  • 9.4.2. BASF SE
    • 9.4.2.1. Company Overview
    • 9.4.2.2. Product Portfolio
    • 9.4.2.3. Financial Overview
    • 9.4.2.4. Business Strategies and Development
  • 9.4.3. Bioduro-Sundia
    • 9.4.3.1. Company Overview
    • 9.4.3.2. Product Portfolio
    • 9.4.3.3. Financial Overview
    • 9.4.3.4. Business Strategies and Development
  • 9.4.4. Bruker
    • 9.4.4.1. Company Overview
    • 9.4.4.2. Product Portfolio
    • 9.4.4.3. Financial Overview
    • 9.4.4.4. Business Strategies and Development
  • 9.4.5. Cambrex Corporation
    • 9.4.5.1. Company Overview
    • 9.4.5.2. Product Portfolio
    • 9.4.5.3. Financial Overview
    • 9.4.5.4. Business Strategies and Development
  • 9.4.6. Croda International Plc
    • 9.4.6.1. Company Overview
    • 9.4.6.2. Product Portfolio
    • 9.4.6.3. Financial Overview
    • 9.4.6.4. Business Strategies and Development
  • 9.4.7. Aragen Life Sciences Pvt. Ltd
    • 9.4.7.1. Company Overview
    • 9.4.7.2. Product Portfolio
    • 9.4.7.3. Financial Overview
    • 9.4.7.4. Business Strategies and Development
  • 9.4.8. Eurofins DiscoverX Corporation
    • 9.4.8.1. Company Overview
    • 9.4.8.2. Product Portfolio
    • 9.4.8.3. Financial Overview
    • 9.4.8.4. Business Strategies and Development
  • 9.4.9. NanoCellect Biomedical
    • 9.4.9.1. Company Overview
    • 9.4.9.2. Product Portfolio
    • 9.4.9.3. Financial Overview
    • 9.4.9.4. Business Strategies and Development
  • 9.4.10. Sartorius AG
    • 9.4.10.1. Company Overview
    • 9.4.10.2. Product Portfolio
    • 9.4.10.3. Financial Overview
    • 9.4.10.4. Business Strategies and Development

10. Appendix

• 10.1. Research Methodology
• 10.2. Report Assumptions
• 10.3. Acronyms and Abbreviations